Contents

Netarsudil

Edited by:

Last updated: February 8th, 2022

Menu

Summary of Evidence

Netarsudil vs Timolol

Netarsudil was noninferior to timolol in patients with baseline IOP <27 mm Hg and <30 mm Hg.(ROCKET-4, 2019) {Khouri AS, Serle JB, Bacharach J, Usner DW, Lewis RA, Braswell P, Kopczynski CC, Heah T. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study. Am J Ophthalmol. 2019 Aug;204:97-104.}

 

Netarsudil (od and bd dosing) was non-inferior to timolol in patients with maximum baseline IOP < 25 mm Hg.(ROCKET-1 and -2, 2018) {Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, Novack GD, Kopczynski CC. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018 Feb;186:116-127.}

Evidence

1. Background

2. Safety and efficacy

2.1 Comparative effectiveness

2.1.1 Netarsudil vs Timolol

Clinical Trial

2019 Khouri et.al. (ROCKET-4)

Article link | Archive link | Metrics cited by count

2019
Clinical Trial

Netarsudil was noninferior to timolol in patients with baseline IOP <27 mm Hg and <30 mm Hg. {Khouri AS, Serle JB, Bacharach J, Usner DW, Lewis RA, Braswell P, Kopczynski CC, Heah T. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study. Am J Ophthalmol. 2019 Aug;204:97-104.}

  • Randomized controlled trial of netarsudil 0.02% daily vs Timolol 0.5% bd in patients with bilateral open angle glaucoma or ocular hypertension (186 patients)
  • Findings:
    • Netarsudil was noninferior to timolol in patients with baseline IOP <27 mm Hg and <30 mm Hg.
    • IOP lowering effect was sustained at 6 months.
    • The most common adverse effect was conjunctival hyperaemia (47.9%), mostly mild.
Outcomes Netarsudil bd Timolol bd
Mean decrease from baseline IOP (mmHg) 3.9-4.7 3.8-5.2

Khouri et.al. (ROCKET-4)
Journal full text Archive Metrics

cited by count
Clinical Trial

2018 Serle et.al. (ROCKET-1 and 2)

Article link | Archive link | Metrics cited by count

2018
Clinical Trial

Netarsudil (od and bd dosing) was non-inferior to timolol in patients with maximum baseline IOP < 25 mm Hg {Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, Novack GD, Kopczynski CC. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018 Feb;186:116-127.}

  • Randomized controlled trial of netarsudil 0.02% daily vs netarsudil 0.02% bd vs Timolol 0.5% bd in patients with bilateral open angle glaucoma or ocular hypertension (1167 patients)
Outcomes Netarsudil daily Netarsudil bd Timolol bd
Mean decrease from baseline IOP (mmHg) 3.3-4.6 4.1-5.4 3.7-5.1
Reduction in IOP 16-21% 22-24% 18-23%

Serle et.al. (ROCKET-1 and 2)
Journal full text Archive Metrics

cited by count

References

Comments

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

© 2025 - sourceshed